| Literature DB >> 33384555 |
Agustín Seoane1, Xènia Font1, Juan C Pérez1, Rocío Pérez1, Carlos F Enriquez1, Miriam Parrilla1, Faust Riu1, Josep M Dedeu1, Luis E Barranco1, Xavier Duran2, Inés A Ibáñez1, Marco A Álvarez1.
Abstract
BACKGROUND: Colonoscopy attendance is a key quality parameter in colorectal cancer population screening programmes. Within these programmes, educative interventions with bidirectional contact carried out by trained personnel have been proved to be an important tool for colonoscopy attendance improvement, and because of its huge clinical and economic impact, they have been widely implemented. However, outside of this population programmes, educative measures to improve colonoscopy attendance have been poorly studied and no navigation interventions are usually performed. AIM: To investigate the clinical and economic impacts of an educational telephone intervention on colonoscopy attendance outside colorectal cancer screening programmes.Entities:
Keywords: Colonoscopy; No-show patients; Nursing education; Patient compliance; Quality improvement; Telephone intervention
Mesh:
Year: 2020 PMID: 33384555 PMCID: PMC7754547 DOI: 10.3748/wjg.v26.i47.7568
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Figure 1Patient flow chart. ITT: Intention-to-treat; PP: Per-protocol.
Baseline characteristics of the patients
|
|
|
|
|
|
| |||
| Age (yr), mean (SD) | 59.1 (16.2) | 59.9 (16.0) | 0.307 |
| Male sex, | 347 (47) | 363 (48.7) | 0.527 |
| Foreign nationality, | 94 (12.7) | 102 (13.7) | 0.594 |
| Advanced studies, | 148 (20.1) | 149 (20.0) | 0.834 |
| Language barrier, | 67 (9.1) | 53 (7.1) | 0.163 |
|
| |||
| BMI, mean (SD) | 26.7 (4.7) | 26.9 (4.6) | 0.657 |
| Diabetes mellitus, | 126 (17.1) | 125 (16.8) | 0.871 |
| Abdominal/pelvic surgery, | 287 (38.9) | 292 (39.1) | 0.920 |
| Constipation, | 148 (20.1) | 161 (21.6) | 0.469 |
| Anxiety-depression syndrome, | 253 (34.3) | 253 (33.9) | 0.881 |
| Disabled condition, | 29 (3.9) | 33 (4.4) | 0.634 |
| Charlson index, mean (SD) | 0.5 (0.9) | 0.5 (0.9) | 0.322 |
| ASA classification III-IV, | 84 (11.4) | 100 (13.4) | 0.237 |
| High comorbidity burden, | 33 (4.5) | 42 (5.6) | 0.308 |
| Antiaggregants, | |||
| Aspirin | 73 (9.9) | 72(9.7) | 0.798 |
| Clopidogrel | 6 (0.8) | 9 (1.2) | |
| Dual APA | 1 (0.1) | 2 (0.3) | |
| VKA, | 24 (3.3) | 28 (3.8) | 0.600 |
| DOAC, | |||
| Rivaroxaban | 4 (0.5) | 4 (0.5) | 0.735 |
| Apixaban | 8 (1.1) | (1.2) | |
| Dabigatran | 3 (0.4) | 5 (0.7) | |
|
| |||
| Previous endoscopy, | 335 (45.4) | 323 (49.1) | 0.417 |
| Previous non-attendance, | 77 (10.4) | 86 (11.5) | 0.500 |
| Referring physician, | |||
| Primary care | 668 (90.5) | 684 (91.7) | 0.128 |
| Gastroenterologist | 70 (9.5) | 62 (8.3) | |
| Indication, | |||
| Surveillance | 211 (28.6) | 197 (26.4) | 0.620 |
| Diagnostic | 456 (61.8) | (63.3) | |
| Family history of CRC | 71 (9.6) | 77 (10.3) | |
| Waiting time (d), mean (SD) | 60.7 (56.6) | 59.5 (60.9) | 0.701 |
| Afternoon timetable, | 467 (63.3) | 746 (67.3) | 0.104 |
| Laxative, | |||
| MCSP | 102 (15.1) | 80 (12.5) | 0.372 |
| PEG + ascorbate, 2 L | 158 (23.4) | 3.2) | |
| PEG, 4 L | 416 (61.5) | 411 (64.3) | |
| Previous cleansing problems, | 37 (5) | 44 (5.9) | 0.453 |
BMI: Body mass index; ASA classification: American Society of Anaesthesiologists classification; APA: Antiplatelet agent; VKA: Vitamin K antagonist; DOAC: Direct oral anticoagulant; CRC: Colorectal cancer; MCPS: Magnesium citrate plus sodium picosulfate; PEG: Polyethylene glycol.
Bivariable analysis of risk factors for non-attendance
|
|
| |||||
|
|
|
|
|
|
|
|
| Group, | < 0.001 | < 0.001 | ||||
| Intervention | 676 (51.4) | 62 (36.7) | 586 (47.8) | 27 (20.1) | ||
| Control | 639 (48.6) | 107 (63.3) | 639 (52.2) | 107 (79.9) | ||
| Age (yr), mean (SD) | 60.2 (15.7) | 54.2 (18.0) | < 0.001 | 60.62 (15.6) | 53.45 (18.2) | < 0.001 |
| Sex, | 0.640 | 0.527 | ||||
| Female | 683 (51.9) | 91 (53.8) | 626 (51.1) | 75 (56) | ||
| Male | 632 (48.1) | 78 (46.2) | 599 (48.9) | 59 (44) | ||
| Nationality, | < 0.001 | < 0.001 | ||||
| Spanish | 1169 (88.9) | 119 (70.4) | 1092 (89.1) | 96 (71.6) | ||
| Foreign | 146 (11.1) | 50 (29.6) | 133 (10.9) | 38 (28.4) | ||
| Studies, | < 0.001 | < 0.001 | ||||
| Non-advanced | 1033 (78.6) | 154 (91.1) | 947 (77.3) | 121 (90.3) | ||
| Advanced | 282 (21.4) | 15 (8.9) | 278 (22.7) | 13 (9.7) | ||
| Language barrier, | 0.318 | 0.276 | ||||
| No | 1212 (92.2) | 152 (89.9) | 1130 (92.2) | 120 (89.6) | ||
| Yes | 103 (7.8) | 17(10.1) | 95 (7.8) | 14 (10.4) | ||
|
| ||||||
| BMI, mean (SD) | 26.73 (4.6) | 27.76 (4.9) | 0.007 | 26.75 (4.5) | 27.84 (4.9) | 0.010 |
| Diabetes mellitus, | 0.758 | 0.528 | ||||
| No | 1094 (83.2) | 139 (82.2) | 1014 (82.8) | 108 (80.6) | ||
| Yes | 221 (16.8) | 30 (17.8) | 211 (17.2) | 26 (19.4) | ||
| Abdominal/pelvic surgery, | 0.046 | 0.465 | ||||
| No | 790 (60.1) | 115 (60.8) | 728 (59.4) | 84 (62.7) | ||
| Yes | 525 (39.9) | 54 (32.0) | 497 (40.6) | 50 (37.3) | ||
| Constipation, | 0.148 | 0.214 | ||||
| No | 1034 (78.6) | 141 (83.4) | 958 (78.2) | 11 (82.8) | ||
| Yes | 429 (32.6) | 77 (45.6) | 276 (21.8) | 23 (17.2) | ||
| Anxiety-depression syndrome, | 0.001 | 0.002 | ||||
| No | 886 (67.4) | 92 (54.4) | 832 (67.9) | 73 (54.5) | ||
| Yes | 429 (32.6) | 77 (45.6) | 393 (32.1) | 61 (45.5) | ||
| Disabled condition, | < 0.001 | 0.002 | ||||
| No | 1269 (96.5) | 153 (90.5) | 1182 (96.5) | 122 (91.0) | ||
| Yes | 46 (3.5) | 16 (9.5) | 43 (3.5) | 12 (9.0) | ||
| Charlson index, mean (SD) | 0.57 (0.9) | 0.54 (0.9) | 0.771 | 0.57 (0.9) | 0.50 (0.8) | 0.403 |
| ASA classification, | 0.813 | 0.834 | ||||
| I/II | 1151 (87.5) | 149 (88.2) | 1071 (87.4) | 118 (88.1) | ||
| III/IV | 164 (12.5) | 20 (11.8) | 154 (12.6) | 16 (11.9) | ||
| High comorbidity burden, | 0.840 | 0.769 | ||||
| No | 1248 (94.9) | 161 (95.3) | 1163 (94.9) | 128 (95.5) | ||
| Yes | 67 (5.1) | 8 (4.7) | 62 (5.1) | 6 (4.5) | ||
|
| ||||||
| Previous endoscopy, | < 0.001 | < 0.001 | ||||
| No | 697 (53) | 129 (76.3) | 646 (52.7) | 98 (73.1) | ||
| Yes | 618 (47) | 40 (23.7) | 579 (47.3) | 36 (26.9) | ||
| Previous non-attendance, | < 0.001 | < 0.001 | ||||
| No | 1192 (90.6) | 129 (76.3) | 1111 (90.7) | 101 (75.4) | ||
| Yes | 123 (9.4) | 40 (23.7) | 114 (9.3) | 33 (24.6) | ||
| Referring physician, | 0.125 | 0.293 | ||||
| Primary care | 1178 (89.6) | 159 (94.1) | 1101 (89.9) | 125 (93.3) | ||
| Gastroenterologist | 122 (9.3) | 10 (5.9) | 109 (8.9) | 9 (6.7) | ||
| Other specialities | 15 (1.1) | 0 (0.0) | 15 (1.2) | 0 (0) | ||
| Indication, | < 0.001 | < 0.001 | ||||
| Surveillance | 338 (29.5) | 20 (11.8) | 357 (29.1) | 15 (11.2) | ||
| Diagnostic | 793 (60.3) | 135 (79.9) | 744 (60.7) | 107 (79.9) | ||
| Family history of CRC | 134 (10.2) | 14 (8.3) | 124 (10.1) | 12 (9) | ||
| Waiting time (d), mean (SD) | 59.3 (57.4) | 66.2 (68.6) | 0.149 | 58.3 (55.0) | 66.1 (72.4) | 0.134 |
| Endoscopy timetable, | 0.030 | 0.029 | ||||
| Morning | 469 (35.7) | 46 (27.2) | 436 (35.6) | 35 (26.1) | ||
| Afternoon | 846 (64.3) | 123 (72.8) | 789 (64.4) | 99 (73.9) | ||
| Previous cleansing problems, | 0.318 | 0.180 | ||||
| No | 1246 (94.8) | 157 (92.9) | 1159 (94.6) | 123 (91.8) | ||
| Yes | 69 (5.2) | 12 (7.1) | 66 (5.4) | 11 (8.2) | ||
ITT: Intention-to-treat analysis; PP: Per protocol analysis; A: Attendance; NA: Non-attendance; BMI: Body mass index; ASA classification: American Society of Anaesthesiologists classification; CRC: Colorectal cancer.
Multivariable analysis of risk factors for non-attendance
|
|
| |||||
|
|
|
|
|
|
| |
|
| ||||||
| Group | ||||||
| Intervention | 1 | 1 | ||||
| Control | 1.81 | 1.27-2.58 | 0.001 | 3.56 | 2.25-5.64 | < 0.001 |
| Age | 0.98 | 0.97-0.99 | < 0.001 | 0.97 | 0.96-0.98 | < 0.001 |
| Nationality | ||||||
| Spanish | 1 | |||||
| Foreign | 2.69 | 1.77-4.10 | < 0.001 | 2.49 | 1.55-4.00 | < 0.001 |
| Studies level | ||||||
| Non-advanced | 1 | 1 | ||||
| Advanced | 0.47 | 0.27-0.83 | 0.010 | 0.51 | 0.27-0.94 | 0.031 |
|
| ||||||
| BMI | 1.05 | 1.01-1.08 | 0.012 | 1.04 | 1.01-1.09 | 0.027 |
| Anxiety-depression syndrome | ||||||
| No | 1 | 1 | ||||
| Yes | 2.00 | 1.40-2.86 | < 0.001 | 2.02 | 1.35-3.02 | 0.001 |
| High comorbidity burden | ||||||
| No | 1 | 1 | ||||
| Yes | 2.82 | 0.86-9.24 | 0.087 | 3.87 | 1.17-12.85 | 0.027 |
| Disabled condition | ||||||
| No | 1 | 1 | ||||
| Yes | 3.39 | 1.68-6.84 | 0.001 | 3.37 | 1.50-7.58 | 0.003 |
|
| ||||||
| Previous endoscopy | ||||||
| No | 1 | 1 | ||||
| Yes | 0.35 | 0.22-0.56 | < 0.001 | 0.46 | 0.28-0.77 | 0.003 |
| Previous non-attendance | ||||||
| No | 1 | 1 | ||||
| Yes | 2.94 | 1.89-4.58 | < 0.001 | 3.13 | 1.91-5.13 | < 0.001 |
| Previous cleansing problems | ||||||
| No | 1 | 1 | ||||
| Yes | 2.58 | 1.19-5.59 | 0.016 | 2.58 | 1.13-5.85 | 0.024 |
| Endoscopy timetable | ||||||
| Morning | 1 | 1 | ||||
| Afternoon | 1.52 | 1.03-2.23 | 0.033 | 1.62 | 1.04-2.51 | 0.031 |
ITT: Intention-to-treat analysis; PP: Per protocol analysis; BMI: Body mass index; OR: Odds ratio; CI: Confidence interval.
Compliance, rescheduling and patient satisfaction questionnaire
|
|
|
|
|
|
| |||
| Fasting 2-4 h, | |||
| ITT | 464/702 (66.2) | 427/720 (59.3) | 0.007 |
| PP | 408/583 (70.1) | 427/720 (59.3) | < 0.001 |
| Split regimen, | |||
| ITT | 622/702 (88.6) | 572/719 (79.6) | < 0.001 |
| PP | 544/583 (93.3) | 572/719 (79.6) | < 0.001 |
| Correct diet, | |||
| ITT | 633/702 (90.2) | 593/720 (82.4) | < 0.001 |
| PP | 553/583 (94.9) | 593/720 (82.4) | < 0.001 |
| Complete intake, | |||
| ITT | 597/702 (85) | 554/720 (76.9) | < 0.001 |
| PP | 522/583 (89.5) | 554/720 (76.9) | < 0.001 |
| Cleansing compliance, | |||
| ITT | 433/702 (61.7) | 379/720 (52.6) | 0.001 |
| PP | 383/583 (65.7) | 379/720 (52.6) | < 0.001 |
| Antithrombotic drugs, | |||
| ITT | 37/40 (92.5) | 27/43 (62.8) | 0.001 |
| PP | 33/35 (94.3) | 27/43 (62.8) | 0.001 |
| Endoscopy with anaesthesiologist, | |||
| ITT | 26/33 (78.8) | 0/42 (0) | < 0.001 |
| PP | 26/26 (100) | 0/42 (0) | < 0.001 |
|
| |||
| Global rescheduling, | |||
| ITT | 2/676 (0.3) | 15/639 (2.3) | 0.001 |
| PP | 1/586 (0.2) | 15/639 (2.3) | 0.001 |
|
| |||
| Percentage of excellent (item 8), | |||
| ITT | 195/382 (51) | 97/373 (26) | < 0.001 |
| PP | 171/346 (49.4) | 97/373 (26) | < 0.001 |
| Information score (item 8) | |||
| ITT, mean (SD) | 3.29 (0.88) | 2.80 (1) | < 0.001 |
| PP, mean (SD) | 3.31 (0.89) | 2.80 (1) | < 0.001 |
| Total score of the questionnaire | |||
| ITT, mean (SD) | 26.12 (3.76) | 25.43 (3.82) | 0.01 |
| PP, mean (SD) | 26.18 (3.87) | 25.43 (3.82) | 0.008 |
ITT: Intention-to-treat analysis; PP: Per protocol analysis.